publications
Here we share our own original research work in collaboration with other scientists, where you can gain insight into our experience, expertise, and recognition in the field of research.
KRAS TARGETING
- WITH FARNESYL -
TRANSFERASE
INHIBITORS
Combination of Farnesyl-Transferase Inhibition with KRAS G12D Targeting Breaks Down Therapeutic Resistance in Pancreatic Cancer.
Molnár E, Baranyi M, Szigeti K, Hegedűs L, Bordás F, Gábriel Z, Petényi G, Tóvári J, Hegedűs B, Tímár J.
Pathol Oncol Res. 2024, 30:1611948.
PEPTIDE-DRUG
CONJUGATES
In Vitro and In Vivo Evaluation of Bombesin-MMAE Conjugates for Targeted Tumour Therapy.
Gomena J, Modena D, Cordella P, Vári B, Ranđelović I, Borbély A, Bottani M, Vári-Mező D, Halmos G, Juhász É, Steinkühler C, Tóvári J, Mező G.
Eur J Med Chem. 2024, 277:116767.
MAPPING PROTEIN
BINDING SITES
Mapping Protein Binding Sites by Photoreactive Fragment Pharmacophores.
Ábrányi-Balogh P, Bajusz D, Orgován Z, Keeley AB, Petri L, Péczka N, Szalai TV, Pálfy G, Gadanecz M, Grant EK, Imre T, Takács T, Ranđelović I, Baranyi M, Marton A, Schlosser G, Ashraf QF, de Araujo ED, Karancsi T, Buday L, Tóvári J, Perczel A, Bush JT, Keserű GM.
Commun Chem. 2024, 7(1):168.
KRAS TARGETING
- Gluing GAP to RAS mutants
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development.
Ranđelović I, Nyíri K, Koppány G, Baranyi M, Tóvári J, Kigyós A, Tímár J, Vértessy BG, Grolmusz V.
Int J Mol Sci. 2024, 25(5):2572.
KRAS TARGETING
– with FARNESYL-TRANSFERASE inhibitors
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M, Molnár E, Hegedűs L, Gábriel Z, Petényi FG, Bordás F, Léner L, Ranđelović I, Cserepes M, Tóvári J, Hegedűs B, Tímár J.
Br J Cancer. 2024.
PDTX
Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets.
Tóvári J, Vári-Mező D, Surguta SE, Ladányi A, Kigyós A, Cserepes M.
Cells. 2023, 12(14), 1919.
PEPTIDE-DRUG CONJUGATES
Optimizing the Enzymatic Release of MMAE from isoDGR-based Small Molecule Drug Conjugate by Incorporation of a GPLG-PABC Enzymatically Cleavable Linker.
Zambra M, Ranđelović I, Talarico F, Borbély A, Svajda L, Tóvári J, Mező G, Bodero L, Colombo S, Arrigoni F, Fasola E, Gazzola S, Piarulli U.
Front Pharmacol. 2023, 14:1215694.
KRAS TARGETING
- FRAGMENT SCREENING
Activation-Free Sulfonyl Fluoride Probes for Fragment Screening.
Petri L, Ábrányi-Balogh P, Csorba N, Keeley A, Simon J, Ranđelović I, Tóvári J, Schlosser G, Szabó D, Drahos L, Keserű GM.
Molecules. 2023, 28(7):3042.
KRAS targeting
Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency.
Orgován Z, Péczka N, Petri L, Ábrányi-Balogh P, Ranđelović I, Tóth S, Szakács G, Nyíri K, Vértessy B, Pálfy G, Vida I, Perczel A, Tóvári J and Keserű GM.
Eur J Med Chem. 2023, 115212.
PEPTIDE-DRUG CONJUGATES
Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy: Development of Bombesin-Based Peptide–Drug Conjugates.
Gomena L, Vári B, Oláh-Szabó R, Biri-Kovács B, Bősze S, Borbély A, Soós A, Ranđelović I, Tóvári J and Mező G.
Int. J. Mol. Sci. 2023, 24(4), 3400.
ALZHEIMER’S DISEASE INHIBITORS
Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo.
Stern N, Gacs A, Tátrai E, Flachner B, Hajdú I, Dobi K, Bágyi I, Dormán G, Lőrincz Z, Cseh S, Kígyós A, Tóvári J, Goldblum A.
Int J Mol Sci. 2022 Oct 28;23(21):13098.
PARKINSON’S DISEASE VACCINE
A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine Induces Potent Immune Responses and Therapeutic Efficacy in Mice.
Schmidhuber S, Scheiblhofer S, Weiss R, Cserepes M, Tóvári J, Gadermaier G, Bezard E, De Giorgi F, Ichas F, Strunk D, Mandler M.
Vaccines (Basel). 2022 Aug 30;10(9):1432.
KRAS targeting
Allele-specific inhibitors of mutant KRAS are in the focus of RASopathy consortium.
Nyíri K, Koppány G, Pálfy G, Vida I, Tóth S, Orgován Z, Ranđelović I, Baranyi M, Molnár E, Keserû MG, Tóvári J, Perczel A, Vértessy BG, Tímár J.
Magy Onkol. 2019; 9;63(4):310-323.
FAK INHIBITOR
The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.
Laszlo V, Valko Z, Ozsvar J, Kovacs I, Garay T, Hoda MA, Klikovits T, Stockhammer P, Aigner C, Gröger M, Klepetko W, Berger W, Grusch M, Tovari J, Waizenegger IC, Dome B, Hegedus B.
J Mol Med (Berl). 2019; 97(2):231-242.
ANGIOGENESIS INHIBITION
Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo.
Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirok A, Garay T, Stiglbauer A, Helbich TH, Gröger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B.
Clin Cancer Res. 2018; 24(15):3729-3740.